Floatz logo

Aclarubicin

Relapse Leukemia

Sun Yat-sen UniversitySmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

125 Active assets in the Relapse Leukemia cohort.

Asset / SponsorPhaseRating
VINCRISTINE SULFATE
Inhye Ahn
Phase 3BB
ASPARAGINASE
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 3BB
THIOGUANINE ANHYDROUS
Incyte Corporation
Phase 3BB
Idarubicine
Affiliated Hospital of Nantong University
Phase 3BB
Daunorubicin
Richard Stone, MD
Phase 3BB

View all 50 →

Same molecule, other indications

Aclarubicin is also rated in:

acute myeloid leukemiaDormant
B
Indicative ·
63 / 100
View asset →
Induction ChemotherapyDormant
B
Indicative ·
60 / 100
View asset →
LisaftoclaxDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →